Linvoseltamab Shows Rapid Clinical Activity in Systemic Light Chain Amyloidosis

Linvoseltamab demonstrated rapid clinical activity in patients with relapsed or refractory systemic light chain amyloidosis, according to results from a phase 1/phase 2 trial presented at the ASCO Annual Meeting on May 29, 2026.

The trial focused on patients who had failed previous therapies for systemic light chain amyloidosis, a condition where abnormal proteins build up in organs and impair their function.

Of the 20 patients treated with linvoseltamab, every participant achieved an objective response. 18 of the 20 patients reached a hematologic complete response.

Researchers characterized the safety profile of the drug, known by the brand name Lynozyfic and developed by Regeneron, as manageable. No dose-limiting toxicities were reported during the study period.

The trial investigators noted that the speed and depth of the hematologic responses observed in this patient group were unprecedented.

Understanding Systemic Light Chain Amyloidosis

Systemic light chain amyloidosis is a rare plasma cell disorder. It occurs when plasma cells in the bone marrow produce abnormal light chain proteins.

These misfolded proteins aggregate into insoluble fibrils called amyloid, which deposit in various organs. The most critical accumulations often occur in the heart and kidneys, leading to heart failure or renal failure.

Because the disease progresses by damaging vital organs, the primary goal of treatment is to stop the production of the toxic light chains as quickly as possible to prevent further organ damage.

Mechanism of Linvoseltamab

Linvoseltamab is a bispecific antibody designed to target B-cell maturation antigen (BCMA) and CD3.

BCMA is highly expressed on the surface of malignant plasma cells, which are the cells responsible for producing the abnormal light chains in amyloidosis.

By binding to both BCMA on the plasma cell and CD3 on T-cells, the antibody acts as a bridge. This mechanism redirects the patient’s own T-cells to recognize and destroy the malignant plasma cells.

This approach differs from traditional chemotherapy, which targets rapidly dividing cells more broadly, and aims for a more precise elimination of the disease-causing cells.

Clinical Significance and Safety

For patients with relapsed or refractory disease, treatment options are often limited, and the prognosis can be poor due to cumulative organ damage.

The 100 percent objective response rate observed in this small cohort suggests that linvoseltamab may be effective even in patients who have not responded to other late-line therapies.

The absence of dose-limiting toxicities is a significant finding for this class of therapy. Bispecific antibodies and CAR-T therapies targeting BCMA can sometimes be associated with cytokine release syndrome (CRS) or neurotoxicity.

The researchers’ description of the safety profile as very encouraging indicates that the drug was tolerated well within the parameters of the phase 1/phase 2 trial.

While the results are positive, the small sample size of 20 patients means that larger, randomized controlled trials will be necessary to fully establish the long-term efficacy and safety of linvoseltamab compared to existing standards of care.